mSphere · 2019 · 29 citations · 25 references
Life SciencesMicrobiologyPharmacologyAntimicrobial ResistanceDrug DeliveryMycologyAntifungal AgentsAntifungal ResistanceAntifungal TherapyFungal InfectionsFungal PathogenesisNanomedicineAntifungal Drug ResistanceAntifungal NanomaterialsAntifungal TreatmentsAntimicrobial Growth InhibitionFungal Drug ResistanceFungal Infection TreatmentMultidrug-resistant PathogensNew Antifungal Agents
Advances in medicine have resulted in the discovery and implementation of treatments for human disease. While these recent advances have been beneficial, procedures such as solid-organ transplants and cancer treatments have left many patients in an immunocompromised state. Furthermore, the emergence of immunocompromising diseases such as HIV/AIDS or other immunosuppressive medical conditions have opened an opportunity for fungal infections to afflict patients globally. The development of drug resistance in human-pathogenic fungi and the limited array of antifungal drugs has left us in a scenario where we need to develop new therapeutic approaches to treat fungal infections that are less prone to the development of resistance by pathogenic fungi. The significance of our work lies in utilizing a novel nanoemulsion formulation to treat topical fungal infections while minimizing risks of drug resistance development.
25
Sofía Perea, José L. López-Ribot, William R. Kirkpatrick et al. · Antimicrobial Agents and Chemotherapy · 2001 · 471 citations · Full text